Similar articles for PMID: 18394021

Year	Number of Results
1954	1
1957	1
1958	2
1971	1
1976	2
1977	1
1978	1
1980	3
1981	1
1983	2
1984	1
1985	3
1986	3
1987	4
1989	4
1990	2
1992	1
1993	2
1994	2
1995	4
1996	7
1997	8
1998	7
1999	4
2000	3
2001	2
2002	8
2003	13
2004	21
2005	27
2006	32
2007	49
2008	47
2009	33
2010	19
2011	20
2012	18
2013	31
2014	27
2015	23
2016	14
2017	13
2018	11
2019	9
2020	13
2021	15
2022	17
2023	4
2024	0

1

Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).

Moisey R, Swinburne J, Orme S. Moisey R, et al. Clin Endocrinol (Oxf). 2008 Oct;69(4):642-7. doi: 10.1111/j.1365-2265.2008.03251.x. Epub 2008 Apr 3. Clin Endocrinol (Oxf). 2008. PMID: 18394021

2

Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy.

Lanfranco F, Zitzmann M, Simoni M, Nieschlag E. Lanfranco F, et al. Clin Endocrinol (Oxf). 2004 Apr;60(4):500-7. doi: 10.1111/j.1365-2265.2004.02007.x. Clin Endocrinol (Oxf). 2004. PMID: 15049966

3

A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.

Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. Zhang GY, et al. J Androl. 1998 Nov-Dec;19(6):761-8. J Androl. 1998. PMID: 9876028 Free article.

4

When is bioavailable testosterone a redundant test in the diagnosis of hypogonadism in men?

Gheorghiu I, Moshyk A, Lepage R, Ahnadi CE, Grant AM. Gheorghiu I, et al. Clin Biochem. 2005 Sep;38(9):813-8. doi: 10.1016/j.clinbiochem.2005.05.005. Clin Biochem. 2005. PMID: 15961071

5

Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.

Wang C, Harnett M, Dobs AS, Swerdloff RS. Wang C, et al. J Androl. 2010 Sep-Oct;31(5):457-65. doi: 10.2164/jandrol.109.009597. Epub 2010 Feb 4. J Androl. 2010. PMID: 20133964 Clinical Trial.

6

Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity.

Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Kapoor D, et al. Diabetes Care. 2007 Apr;30(4):911-7. doi: 10.2337/dc06-1426. Diabetes Care. 2007. PMID: 17392552

7

Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.

Morrison BF, Reid M, Madden W, Burnett AL. Morrison BF, et al. Andrology. 2013 Jul;1(4):576-82. doi: 10.1111/j.2047-2927.2013.00084.x. Epub 2013 Apr 18. Andrology. 2013. PMID: 23606509 Free article.

8

Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.

Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G. Okun MS, et al. Arch Neurol. 2006 May;63(5):729-35. doi: 10.1001/archneur.63.5.729. Arch Neurol. 2006. PMID: 16682542 Clinical Trial.

9

Serum total and bioavailable testosterone levels, central obesity, and muscle strength changes with aging in healthy Chinese men.

Chu LW, Tam S, Kung AW, Lo S, Fan S, Wong RL, Morley JE, Lam KS. Chu LW, et al. J Am Geriatr Soc. 2008 Jul;56(7):1286-91. doi: 10.1111/j.1532-5415.2008.01746.x. Epub 2008 May 12. J Am Geriatr Soc. 2008. PMID: 18482300

10

Relative androgen deficiency in relation to obesity and metabolic status in older men.

Chen RY, Wittert GA, Andrews GR. Chen RY, et al. Diabetes Obes Metab. 2006 Jul;8(4):429-35. doi: 10.1111/j.1463-1326.2005.00532.x. Diabetes Obes Metab. 2006. PMID: 16776750

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

464 results

Results by year